Promentis Pharmaceuticals Inc
Directory listingDirectory record status
These labels describe this UNITEMFG record. They do not guarantee current capabilities, certifications, capacity, quality, or fit for a specific job.
- Directory listing
- Listed
- Ownership
- Unclaimed
- Evidence reviewed
- Not recorded
- Last evidence review
- Not recorded
About
Promentis Pharmaceuticals Inc is a privately-held biopharmaceutical company based in Milwaukee, Wisconsin, dedicated to developing innovative therapies for neuropsychiatric disorders. The company specializes in creating novel oral compounds that engage System xc-, a central nervous system target for diverse psychiatric disorders, with their first indication focused on trichotillomania treatment. Operating under the slogan "Redefine What is Possible," Promentis Pharmaceuticals conducts cutting-edge research into glutamate signaling in brain regions related to urge control and executive function. This targeted approach positions the company at the forefront of neuropsychiatric drug development, addressing conditions that currently have no approved therapies available. The Milwaukee-based pharmaceutical company represents a unique player in the biopharmaceutical industry, combining scientific innovation with a focused therapeutic approach. Their research-driven methodology and commitment to addressing unmet medical needs in neuropsychiatric disorders demonstrates their potential to make significant contributions to patient care and treatment outcomes. Located at 826 N. Plankinton Ave., Suite 400, Milwaukee, WI 53203, Promentis Pharmaceuticals continues to advance their pipeline of neuropsychiatric treatments through rigorous research and development processes, positioning themselves as a specialized leader in this challenging therapeutic area.